Adverum Biotechnologies, Inc. financial data

Symbol
ADVM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Cardinal Way, Redwood City, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Avalanche Biotechnologies, Inc. (to 5/10/2016)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 479 % -19.3%
Debt-to-equity 75.9 % +20.4%
Return On Equity -90.4 % -22.8%
Return On Assets -51.4 % -13.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 208 M shares +106%
Common Stock, Shares, Outstanding 101 M shares +1.31%
Entity Public Float 152 M USD +32.1%
Common Stock, Value, Issued 2 K USD -80%
Weighted Average Number of Shares Outstanding, Basic 16.5 M shares +64.3%
Weighted Average Number of Shares Outstanding, Diluted 16.5 M shares +64.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 72 M USD -26%
General and Administrative Expense 48.6 M USD -12.4%
Operating Income (Loss) -121 M USD +19.2%
Nonoperating Income (Expense) 6.6 M USD +81.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -114 M USD +21.7%
Income Tax Expense (Benefit) -1.1 M USD -1621%
Net Income (Loss) Attributable to Parent -113 M USD +22.5%
Earnings Per Share, Basic 0.24 USD/shares +48.3%
Earnings Per Share, Diluted 0.24 USD/shares +48.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 150 M USD +121%
Cash, Cash Equivalents, and Short-term Investments 193 M USD +17.7%
Assets, Current 199 M USD +17.9%
Property, Plant and Equipment, Net 13.8 M USD -58.7%
Operating Lease, Right-of-Use Asset 51.8 M USD -25.5%
Other Assets, Noncurrent 1.2 M USD -11.5%
Assets 268 M USD -2.81%
Accounts Payable, Current 1.9 M USD -33.7%
Liabilities, Current 21.5 M USD -53.6%
Operating Lease, Liability, Noncurrent 64 M USD -10.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 85.5 M USD -27.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -533 K USD +33.3%
Retained Earnings (Accumulated Deficit) -945 M USD -13.6%
Stockholders' Equity Attributable to Parent 182 M USD +15.6%
Liabilities and Equity 268 M USD -2.81%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.2 M USD -3.72%
Net Cash Provided by (Used in) Financing Activities 120 M USD
Net Cash Provided by (Used in) Investing Activities -22 M USD -202%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 101 M shares +1.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 74.6 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 152 M USD +116%
Deferred Tax Assets, Valuation Allowance 205 M USD +9.02%
Deferred Tax Assets, Gross 219 M USD +5.41%
Operating Lease, Liability 75 M USD -17.5%
Payments to Acquire Property, Plant, and Equipment 90 K USD +5.88%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -113 M USD +22.4%
Lessee, Operating Lease, Liability, to be Paid 141 M USD -14.8%
Property, Plant and Equipment, Gross 29.3 M USD -43.6%
Operating Lease, Liability, Current 10.5 M USD -60.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.4 M USD -3.45%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.1 M USD -3.47%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 66.2 M USD -11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.8 M USD -3.44%
Deferred Tax Assets, Operating Loss Carryforwards 128 M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 24.6 M USD -0.53%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.2 M USD -3.42%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 13.6 M USD -29.6%
Share-based Payment Arrangement, Expense 17.2 M USD -10.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%